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Abstract: Since COVID-19 pandemic has been continuously rising and spreading, several original contributions and review articles
on COVID-19 started to appear in the literature. The review articles are mainly focus on the current status of the pandemic along
with current status of the corona diagnosis and treatment process. Due to some disadvantages of the currently used methods, the
improvement on the novel promising diagnosis and treatment methods of corona virus is very important issue. In this review, after briefly
discussing the status of current diagnosis and treatment methods, we present to the scientific community, novel promising methods
in the diagnosis and treatment of COVID-19. As with other novel approaches, first, the diagnosis potential of mass spectroscopy and
optical spectroscopic methods such as UV/visible, infrared, and Raman spectroscopy coupled with chemometrics will be discussed
for the corona virus infected samples based on the relevant literature. In vibrational spectroscopy studies, due to complexity of the
data, multivariate analysis methods are also applied to data. The application of multivariate analysis tools that can be used to extract
useful information from the data for diagnostic and characterisation purposes is also included in this review. The reviewed methods
include hierarchical cluster analysis, principal component analysis, linear and quadratic discriminant analysis, support vector machine
algorithm, and one form of neural networks namely deep learning method. Second, novel treatment methods such as photodynamic
therapy and the use of nanoparticles in the in-corona virus therapy will be discussed. Finally, the advantages of novel promising diagnosis
and treatment methods in COVID-19, over standard methods will be discussed. One of the main aims of this paper is to encourage the
scientific community to explore the potential of this novel tools for their use in corona virus characterization, diagnosis, and treatment.
Key words: COVID-19, diagnosis, novel methods, infrared spectroscopy, Raman spectroscopy, nanotechnology

1. Introduction
In December 2019, COVID-19 (2019 coronavirus disease)
caused by SARS-CoV-2 started to spread from Wuhan
City of China, by affecting countries such as Japan,
Thailand, and the Republic of Korea in first place (Zhu et
al., 2020). In March 2020, it was reported by the World
Health Organization (WHO) that COVID-19 has become
a “pandemic” to the whole world1. According to WHO
data, as of May 15, 2021, more than 161 million people
worldwide have been diagnosed with COVID-19, with
1
World Health Organization (WHO) (2020). Advice on the use
of masks in the community, during home care and in healthcare
settings in the context of the novel coronavirus (2019-nCoV)
outbreak: interim guidance [Online]. Website https//www.who.
int/publications-detail/advice-on-the-use-of-masks-in-thecommunityduring home- care-and-in-healthcare-settings-in-thecontext-of-the-novel-coronavirus-(2019-ncov)-outbreak. [accessed
March 9th, 2020].

more than 3.3 million deaths reported2. SARS-CoV-2 has
a genetic affinity with the previous coronaviruses named
SARS-CoV and MERS-CoV which have previously caused
extremely dreadful health threats within two decades (Zhu
et al., 2020).
In COVID-19 patients, although it varies from patient
to patient, the most common clinical symptoms are sore
throat, dry cough, weakness, fever, shortness of breath or
breathing difficulties, and body aches. In addition, patients
may experience nausea, diarrhoea or runny nose (Xu et
al., 2020). In the computerised tomography (CT) scan
results of many COVID-19 patients, bilateral, groundglass opacity with multifocal lung lesions have been
reported even in the early stage of SARS-CoV-2 infection
World Health Organization (WHO) (2021). WHO Coronavirus
(COVID-19) Dashboard [Online]. https://www.who.int. [accessed
May 16, 2021].
2
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(Xu et al., 2020). These ground glass opacities and patchy
consolidations can be seen in infected patients without any
clinical symptoms (Jin et al., 2020).
Polymerase chain reaction (PCR) and reverse
transcriptase (RT)-PCR are common methods for the
detection of SARS-CoV-2, since they are accepted as
reliable methods for virus detection with high sensitivity
and specificity (Li et al., 2020a). Although there are
several RT-PCR-based test kits with high accuracy for
SARS-CoV-2 detection, there are still various limitations
of this application. These limitations include getting
the sufficient genetic material with sampling, the high
cost of the reagents and equipment and getting results
in a long time (Shoaib et al., 2021). Although nucleic
acid amplification tests are widely recommended in the
diagnosis of COVID-19, it is not possible to ignore the
false diagnosis and other serious consequences it may
cause due to false negative or false positives results (Li
et al., 2020a). The similar features on Chest radiography
(CT) scan images of 60%–70% COVID-19 patients were
determined (Forouzesh et al., 2020). Ten days after the
beginning of the disease, the findings of the infection
can be defined in CT results (Dheyab et al., 2021). In
addition, findings of infection can be seen in CT results
of patients who has negative results in nucleic acid-based
tests (Forouzesh et al., 2020). Although CT scanning is
cheaper in Turkey than some other countries and more
easily applicable in secondary centres compared to PCR
test, it is still an expensive imaging system with the need
of technical expert. Moreover, it has low specificity in
the diagnosis of COVID-19 (Shoaib et al., 2021). Besides
these limitations of the technique, the exposure to the
radiation is another handicap for the use of this method
in the diagnosis (Forouzesh et al., 2020). Serum amounts
of immunoglobulin M (IgM) and immunoglobulin G
(IgG) antibodies can be used as indicators for infections.
The combinations of these two antibodies are used for
the determination of the disease severity (Shoaib et al.,
2021). According to the Centers for Disease Control and
Prevention (CDC) recommendation, serological tests
can be used just for the assessment of immunity and
determining if a patient has ever been infected but not for
clinical diagnostics3. Therefore, additional technologies
must be developed to address these shortcomings in the
early diagnosis of COVID-19.
There is not globally known, proven treatment or
drug for COVID-19 disease. On the other hand, there
are some medications recommended for treatment in
official protocols and guidelines in many countries.
Antiprotozoal and antiviral drugs are used in the
3
Centers for Disease Control and Prevention (CDC) (2021).
COVID-19 Testing Overview [Online]. Website https://www.cdc.
gov/coronavirus/2019-ncov/hcp/testing-overview.html
[accessed
March 17th, 2021].

treatment of COVID-19 patients. In addition to these
drugs, antipyretics or NSAIDs, antibiotics, vasopressors
and anticoagulants, early blood purification, betaagonists, and systemic corticosteroids are generally
recommended as supportive treatment depending on
the prognosis of the disease (Shoaib et al., 2021). As an
adjunctive therapy, the beneficial potential of hyperbaric
oxygen (HBO) therapy cannot be dismissed. Although
the evidence of the beneficial effects of HBO therapy in
COVID-19 patients is limited, there are several clinical
studies reported that early application of this technique
can promote the recovery of the patients (Gorenstein et
al. 2020; Zhan et al. 2020; Harrison et al. 2021). The use
of chloroquine (CQ) and hydroxychloroquine (HCQ) as
antiprotozoal drugs was not supported by WHO2 due to
their failure in treatment and side effects especially hearth
diseases when used with other drugs (Saghir et al., 2021).
Some of the antiviral drugs (remdesivir, lopinavir, and
ritonavir) have not shown better results than the other
treatment options used for moderately ill patients, while
the others including favipiravir need additional clinical
studies (Shoaib et al., 2021). In addition, the drug called
REGN-COV2, developed by Regeneron Pharmaceuticals,
was approved by the US FDA on November 21, 2020 for
the treatment of adult mild-to-moderate COVID-19
patients besides the paediatric patients above 12 years old
and 40 kg weight. This drug consists of two monoclonal
antibodies, casirivimab, and imdevimab, and is used in
all hospitalized COVID-19 patients in the United States.
When the drug is used in these patients, it prevents the
prognosis of the disease from worsening and the patients
to enter intensive care4. However, there are limited clinical
data with this drug for the treatment of COVID-19
(Weinreich et al., 2021). Thus, the results of the ongoing
randomized controlled clinical studies should be closely
monitored to determine an optimal treatment strategy in
severe COVID-19 patients.
As COVID-19 continues to spread rapidly as a global
epidemic around the world, research is ongoing for
new diagnostic and therapeutic methods and vaccine
development studies that are more effective than those
currently used.
This review focuses on the new diagnosis and treatment
methods developed as alternatives to current diagnosis
and treatment strategies used against SARS-CoV-2. Thus,
it will shed light on early diagnosis and effective treatment
strategies against possible outbreaks that may occur in the
4
PRNewswire (2021, March 23). Phase 3 Trial Shows REGENCOV™ (casirivimab with imdevimab) Antibody Cocktail Reduced
Hospitalization or Death by 70% in Non-hospitalized COVID-19
Patients [Online]. Website https://www.prnewswire.com/newsreleases/phase-3-trial-shows-regen-cov-casirivimab-withimdevimab-antibody-cocktail-reduced-hospitalization-or-deathby-70-in-non-hospitalized-covid-19-patients-301253401.html
[accessed May 19, 2021].

359

GARİP-USTAOĞLU et al. / Turk J Biol
future due to similar coronaviruses. In this review, brief
descriptions of the current diagnostic and therapeutic
methods were also given with their advantages and
disadvantages. There are a great number of reviews related
to the action mechanism of SARS-CoV-2, the prognosis,
diagnosis, and treatment strategies of COVID-19 since
2020 in the literature. However, this review is a very
comprehensive resource that both summarizes currently
used techniques and focuses on promising cutting-edge
technologies and applications for the diagnosis and
treatment of COVID-19.
2. Current diagnostic methods
Currently, nucleic acid polymerase chain reaction (PCR)
test results are still the gold standard for the diagnosis
of COVID-19, and serological tests such as IgG/IgM
detection can be used in addition to the nucleic acid
test (Ye et al., 2021). Although SARS-CoV-2 can also be
detected in various body samples including throat swabs,
the upper and lower respiratory tract, serum, urine and
feces samples, the use of oropharyngeal swab samples can
increase the accuracy of detecting the virus compared
to using nasopharyngeal samples, by also reducing the
difficulty of sample collection and patient pain. In addition,
sputum has been reported to give the highest positive rate
with 74.4%−88.9% in the diagnosis of COVID-19 within
the first 14 days of the onset of the disease (Zhang et al.,
2021).
Currently, there are three main direct and indirect
detection methods as Nucleic acid ampliﬁcation test
for direct detection, and radiological examination and
serological tests as indirect detection methods.
2.1. Nucleic acid tests
PCR and RT-PCR are accepted as important nucleic acidbased tests depending on a detection of a specific gene
(Shoaib et al., 2021). These methods are commonly used
for the determination of SARS-CoV-2, since they are
accepted as reliable methods with high sensitivity and
specificity for pathogenic virus detection (Li et al., 2020a).
RT-PCR which uses RNA template is more recommended
than PCR using DNA template (Shen M. et al., 2020).
Various RT-PCR-based test kits with 95% accuracy for
SARSCoV-2 detection have been developed (Li et al.,
2020a). However, to get a reliable PCR-based diagnosis,
sufficient sample from the patient, proper handling and
storage of these samples and adequate genetic material is
needed (Shoaib et al., 2021). In addition, these procedures
are expensive techniques that require costly reagents and
equipment and give results in a long time. One of the
biggest problems in detecting SARS-CoV-2 with these
techniques is that safe and stable external positive controls
for SARS-CoV (previous coronavirus) are not yet available
for SARS-CoV-2 (Shen et al., 2020).
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It has been stated that the loop mediated isothermal
ampliﬁcation (LAMP) technique, also known as a new
ultra-sensitive isothermal nucleic acid amplificationbased method, overcomes time-consuming feature and
expensiveness of RT-PCR. The advantage of the technique
is that it provides results in less than an hour without using
expensive reagents or equipment, as well as using a small
amount of sample (Tarim et al., 2021). Many studies have
initiated clinical applications with RT-LAMP tests with
88.89% sensitivity and 99.00% specificity for the diagnosis
of COVID-19 (Hu et al., 2020; Dheyab et al., 2021).
However, the requirement for high temperature (mainly
65 °C) and optimization problems related to primers and
reaction parameters limit the application of this technique
(Shen et al., 2020).
The “speciﬁc high-sensitivity enzymatic reporter
unlocking” method, which is a nucleic acid detection
technique based on CRISPR (clustered regularly
interspaced short palindromic repeats), combines the
LAMP method with the Cas13 enzyme. There is a couple
of at-home assays with FDA approval (FDA emergency
use authorization) based on CRISPR-Cas13 method for
the portable, rapid, and highly sensitive determination of
SARS-CoV-2 (Shen et al., 2020).
2.2. Radiological examination
Computerized tomography (CT) of chest is accepted in
clinical practice as a reliable method for the diagnosis of
COVID-19. The same features including bilateral, groundglass opacity with multifocal lung lesions are observed
on CT scan images of approximately 60% to 77% of
COVID-19 cases (Forouzesh et al., 2020). While normal
CT findings are observed in more than half of the patients
at the first stage of infection (0–2 days), approximately
10 days after the onset of symptoms, the highest lung
involvement is reported in CT findings (Dheyab et al.,
2021). The limitations of this technique include high cost
of the imaging system, requirement for a technical expert
and low specificity (25%) in the diagnosis of COVID-19.
Although it is reported to have a low specificity, Kovács
et al. (2021) stated that CT scans have higher specificity
when the low sensitivity of the RT-PCR is considered. It
is reported that especially in the patients with negative
RT-PCR result with the symptoms of the infection, the use
of chest CT has an importance for the diagnosis (Kovács
et al., 2021). On the other hand, the CT imaging features
seen COVID-19 patients can be overlapped with the
characteristic feature of other viral pneumonias (Shoaib
et al., 2021). Moreover, especially pregnant women and
children need to be avoided from frequent radiation
exposure (Forouzesh et al., 2020).
2.3. Serological tests
Although direct diagnostic methods such as specific
antigen- or nucleic acid-based methods, are preferred in
the diagnosis of COVID-19, indirect detection methods
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are also widely used in research and clinics. These
methods are based on the evaluation of antibodies which
are produced as a response when there is an infection in
the patient. However, these methods have lower accuracy
and specificity compared to direct diagnostic methods
(Dheyab et al., 2021).
Serum levels of IgM and IgG which are the antibodies
produced in the patient’s body after an infection, can be
used as indicators for SARS-CoV-2 infection. The levels
of IgM antibody can be used in the early stage of the
infection, while IgG antibody levels show variations in the
middle or late period of the infection (Tarim et al., 2021).
Lateral flow IgM and IgG detection for SARS-CoV-2
is one of the point-of-care techniques which is being
developed for COVID-19 diagnosis. Lateral flow has 57%
clinical sensitivity, 100% specificity and 69% accuracy for
IgM, while these percentages are 81 %, 100 %, and 86% for
IgG, respectively (Dheyab et al., 2021).
The enzyme-linked immunospot assay (ELISpot) which
is also known as interferon gamma release assay (IGRAs),
detects SARS-CoV-2 by measuring the interferon (IFN)gamma release from T cells in response to the antigens
of COVID-19. In the study of Schwarzkopf et al. (2021),
it was reported that 78% of PCR-positive patients with
undetectable IgG antibodies was successfully detected by
using interferon-γ ELISpot assay (Schwarzkopf et al., 2021).
However, in another current study, 44% of unexposed
healthy patients with an IgG-RBD seronegative, had also a
strong T-cell response in the results of COVID-19 ELISpot
test. They suggested that this could be caused by a prior
exposure to other coronaviruses (Echeverría et al., 2021).
It has been reported that these tests may cause
false negative results in patient, as a large population
in the community is already exposed to other human
coronaviruses with high similarity to SARS-CoV-2 (Lee
et al., 2020). According to the recommendations of CDC
(Centers for Disease Control and Prevention), serological
tests should not be used for clinical diagnostics but just for
the assessment of immunity and determining if a patient
has ever been infected1.
There are also other serological markers which are used
for monitoring the severity of the infection and course of
the disease in the COVID-19 patients such as interleukins
(IL-6, IL-10, and IL-2R), erythrocyte sedimentation rate
(ESR), complete blood count (CBC), prothrombin time
(PT), and related enzymes of liver, kidney, and heart
tissues (Forouzesh et al., 2020).
Due to the limitations of the current methods,
additional technologies must be developed to address
these shortcomings in the diagnosis of SARS-CoV-2.
3. Promising novel diagnosis approaches
The most commonly available methods in diagnostic
clinics or hospitals are serological and nucleic acid-

based methods. For these purposes, enzyme-linked
immunosorbent assay (ELISA) and RT-qPCR methods are
widely used. These methods are time-consuming, costly,
and not always accurate. In addition, due to shortage
of testing facilities the samples have to be transported to
available centres which increase the cost and duration
of getting the results. There is an urgent need for rapid,
inexpensive, sensitive, operator independent diagnostic
tool to detect coronavirus 2 [SARS-CoV-2] infections.
3.1. Vibrational spectroscopic techniques
Spectroscopic techniques are based on the interaction
of electromagnetic radiation with matter. Vibrational
spectroscopy mainly includes infrared and Raman
spectroscopy. In infrared spectroscopy, infrared radiation
interacts with matter. In Raman spectroscopy, the
radiation corresponding the electronic energy levels is
used but as a low probability event, the transition between
the vibration energy levels is detected. These vibrational
techniques coupled with chemometric methods are very
good candidate to detect viruses including corona virus
(COVID-19) (Pahlow et al. 2018; Santos et al. 2020).
Vibrational spectroscopy and imaging give valuable
molecular information without the need for stains or dyes
and with rapid collection all of which simplify and speed
up necessary analyses for detection. Other advantages of
the techniques will include requirement of less sample size,
operator independency and accuracy while not requiring
extensive specialized human expertise that stimulate the
vibrational techniques to go from bench to bed site.
3.1.1. Infrared spectroscopy
Fourier-transform infrared (FTIR) spectroscopy,
especially attenuated total reflection fourier-transform
infrared (ATR-FTIR) spectroscopy coupled with
multivariate analysis methods is a very good candidate
for disease diagnosis including virus-infected samples.
When ATR mode is used, very small amount of sample,
for example a one drop of bio fluids, is directly put on
the top of the crystal and with the improved infrared
spectrometers noise free spectral data are collected
in a very short time. In addition, FTIR spectroscopy
is a rapid, cost-effective, easy to use, nondestructive,
operator independent technique. It was also shown
that this technique is independent of the mode whether
transmission or reflection mode is used (Gok et al, 2016).
These properties make this technique a perfect candidate
for translation from bench to clinic. Pathological situations
induce structural and functional changes in molecules of
biological systems. These changes may cause variations in
vibrational energy levels which can be detected by infrared
spectroscopy (Yonar et al., 2018). Up to now, complex, and
large infrared spectral data combined with multivariate
analysis methods were successfully employed the diagnosis
of different diseases (Severcan and Haris, 2012; Gok et al.,
2016; Yonar et al., 2018). Tissue sections, any cytological
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and histological samples or biofluids can be studied by
infrared spectroscopy (Severcan and Haris, 2012).
In a recent review article, the use of ATR-FTIR coupled
with multivariate analysis techniques for classification
and detection of different viruses such as hepatitis C
and B, dengue, zika and chikungunya, were summarized
with the aim of using this approach in corona virus
detection. The effectiveness of multivariate analysis
methods such as principle component analysis (PCA),
successive projections algorithm (SPA), genetic algorithm
(GA), linear discriminant analysis (LDA), and quadratic
discriminant analysis (QDA) were discussed. At the end, it
was proposed that ATR-FTIR spectroscopy at mid infrared
region can be successfully applied to the detection of
COVID-19 virus (Santos et al., 2020). After the pandemic,
in last two years, the articles related to the use of FTIR
spectroscopy in the diagnosis of COVID-19 has been
started to appear in the literature. Barauna and co-workers
(2021) first performed laboratory work with spiking of
saliva with inactivated COVID-19 virus using ATR-FTIR
spectroscopy. It was shown that the virus induced dramatic
changes in the nucleic acid bands including RNA. Then,
they worked at clinical level with healthy and infected
pharyngeal swabs. Swab samples were divided into two
categories as negative and positive COVID-19 infection
based on symptoms and PCR results (n = 111 negatives
and 70 positives). The ATR-FTIR spectra were collected,
and then principal component analysis (PCA) was applied
to spectra. Following training and validation with the
use of 61 negatives and 20 positives samples, by applying
genetic algorithm-linear discriminant analysis (GA-LDA)
algorithm, 95% sensitivity and of 89% specificity values
were obtained. It was reported that it takes only 2 min to
get the discrimination of the groups and therefore it will
be very useful to use this approach when sudden test is
required such as airports, events, or gate controls.
In the work of Zhang and co-workers (2021) a total
of 115 blood serum samples, 20 of which from healthy
donors, and 76 from infected patients, were studied by
ATR-FTIR spectroscopy. A total of 41 samples were
confirmed as COVID-19, of which 35 were CoV-1 and 6
were CoV-2. The others were from other infectious diseases
such as influenza, inflammation. Detailed characterization
studies indicated significant changes in the band location
of amide A, all the bands (mainly lipid and one weak band
of proteins) in the C-H region, protein amide I and II
and nucleic acid bands. These changes indicate structural
changes in the relevant molecules. Significant changes in
the concentration of lipids, proteins and nucleic acids were
also observed from the signal intensity values. HCA and
PCA unsupervised chemometric tools and a supervised
method namely partial least squares discriminant analysis
(PLS-DA) were applied to the infrared spectra and based
on these spectral variations, the COVID-19 group was
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successfully separated from the nonsevere infected group
and the healthy control group (Figure 1).
3.1.2. Raman spectroscopy and imaging
As a vibrational spectroscopic technique, similar to infrared
spectroscopy, Raman spectroscopy and microspectroscopy
are also promising techniques in disease diagnosis and
screening (Severcan and Haris, 2012). Several papers have
been published related to their applications together with
different multivariant analysis methods on different human
diseases using both cells, tissues, and body fluids (Pahlow
et al., 2018). Raman spectroscopy and microspectroscopy
are also excellent techiques to study COVID-19 virus.
In a recent review (Saviñon-Flores et al., 2021),
mainly basis of surface enhanced Raman scattering
(SERS) technique was reported with some examples
in identification and characterization of infectious
diseases such as influenza (flu) and coronaviruses (CoV),
including COVID-19. In the other study, Carlomagno et
al. (2021) used SERS technique to the saliva of COVID-19
test positive (n = 30) and negative (n = 38) patients and
healthy people as control (N=33) groups. Their results
demonstrated the differences in biomolecular content of
the three experimental saliva groups. They also applied
classification models to Raman spectra such as leave-onepatient-out cross-validation (LOPOCV), support vector
machine (SVM), random forest (RF), extreme gradient
boosting (XGB), and convolutional neural networks
(CNNs). Among these, the most promising results were
obtained by CNNs method which revealed as more than
95% accuracy, sensitivity, and specificity. Using deep
learning model, 89%–92% accuracy was achieved. The
other study also used SERS technique and proposed that,
this technique can perform faster detection of COVID-19
than routinely used PCR (Magdy et al., 2020).
A more detailed study was published recently about
the application of Raman spectroscopy coupled with
multivariate analysis on COVID-19 diagnosis from serum
(Yin et al., 2021). Since it is also very important to detect
suspected case which consists of patients with flu symptoms
or individuals in tight contact with COVID-19 patients,
this group also was included to the experimental groups. A
total of 177 serum samples were studied, of which 63 were
confirmed COVID-19 patients, 59 suspected cases, and 55
healthy individuals as a control group. The Raman spectra
of the COVID-19 infected group were very different than
those of other groups. As multivariate analysis machine
learning support-vector machine (SVM) method was
applied to the Raman spectra to separate the experimental
groups. A very good separation was obtained between
the groups. The accuracy, sensitivity, and specificity
values obtained clearly showed that COVID-19 infected
group successfully differentiated from the other groups.
Furthermore, in this study external validation was applied
using 20 independent samples, 5 of which asymptomatic
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Figure 1. Discrimination among normal controls and nonsevere and severe COVID-19 patients with
unsupervised methods. (a,b) PCA score plot using spectral ranges of 1600−1700 cm−1 and 1000−1700 cm−1,
respectively. Spectra from three patients are marked with arrows. NS = nonsevere. S = severe. (c) Hierarchical
cluster analysis (1000−1700 cm−1). The windows corresponding to the three groups are filled with different
colors. 1 = normal controls; 2 = nonsevere COVID-19 patients; 3 = severe COVID-19 patients. [reprinted
with permission from Zhang et al., 2021].

COVID-19 patients and 5 symptomatic COVID-19
patients, 5 suspected patients, and 5 healthy patients. The
model showed that classification results were all correct for
independent test dataset. This study suggests that Raman
spectroscopy could be a safe and efficient technique for
COVID-19 diagnosis and screening.
3.2. Mass spectrometry (MS)-based omics technologies
Mass spectrometry (MS)-based omics technologies such
as proteomics, glycomics, lipidomics, and metabolomics,
has been used for the detection and identification of
microbial agents like SARS-CoV-2. MS technologies
provide the instant picture of pathogen related changes
in the host. SARS-CoV-2 infections and pathogenesis has
been searched in the COVID-19 patient’s materials and

cellular model systems by MS-based omics technologies
(Mahmud and Garrett, 2020). PCR-MS has directly
identified all known pathogens in the clinical specimens
and detected gene sequences of undiscovered pathogens
(Wolk et al., 2012). Matrix-assisted laser desorption/
ionization combined with mass spectrometry (MALDIMS) is an advanced method for the diagnosis of COVID-19
by using minimal specimens, a few reagents, easy to handle
protocol and fast data acquisition system but MALDIMS is currently an expensive tool for many laboratories
in the world (Nachtigall et al., 2020). As conclusion,
MS-based technologies are the advanced techniques for
determination of pathogen outbreaks such as COVID-19.
For the detection of respiratory viruses including
SARS-CoV-2, there are other new studies to develop many
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more original and innovative optical detection methods
using absorbance, surface plasmon resonance, localized
surface plasmon resonance, fluorescence, and colorimetric
techniques in microfluidic devices. These techniques have
advantages such as low sample volume, short assay time,
low cost, being portable and precise (Dheyab et al., 2021;
Tarim et al., 2021). However, these methods are still under
development and cannot be used for direct diagnosis of
COVID-19.
4. Current therapeutic methods
4.1. UV-based disinfection technologies
Ultraviolet (UV) technologies have been intensively used
for disinfection of hospitals and medical equipment for
decades. UV can kill the microorganisms and inactivates
viruses including SARS-CoV-2 in all surfaces. SARSCoV-2 can survive on surfaces for up to 9 days. The effects
of UV germicidal irradiation (UVGI, UV-C irradiation
at 254 nm) on SARS-CoV-2 depend on culture medium,
SARS-CoV-2 concentration, UV-C dose, irradiation time
and UV-C absorbance (Biasin et al., 2021). Furthermore,
UV-C can cause skin cancer and cataracts in humans.
Thus, UVGI protocols for inactivation of SARS-CoV-2
and disinfection of used personal protective equipment are
needed to develop by concerning the safety of UV devices
(Raeiszadeh and Adeli, 2020). On the other hand, UV-B
radiation (up to 20 min) can inactivate the SARS-CoV-2
on surfaces. Also, UV-B enhances the synthesis of vitamin
D which leads to protective effects against COVID-19
patients by increasing immunity (Ratnesar-Shumate et al.,
2020).
4.2. Treatment with antiviral drugs
Over 80 antiviral drugs are approved for treatment
of viral infections, including HIV, Ebola, influenza A
and B, hepatitis A and C, herpes simplex and human
papillomavirus (De Clercq and Li, 2016). After the
outbreak of COVID-19 pandemic, several antiviral agents
have been used in order to treat the disease, and the reports
are numerous. Several review articles are already reviewed
this topic again repeatedly, and in this part the findings
of some of these review articles as well as original reports
have been discussed.
There are several reports on favipiravir treatment.
These include a study in China with 80 patients where they
received 1600 mg twice on the first day and 600 mg twice
a day on between 2nd–14th days with interferon-α aerosol
inhalation (Cai et al., 2020). Results were promising as
favipiravir treatment showed less adverse effects and better
therapeutic effects. Several systematic reviews also show
the use of favipiravir treatment is a good option thanks to
rapid viral clearance and fast clinical improvement (Joshi
et al., 2021). Currently, favipiravir is among the antiviral
agents used in COVID-19 treatment worldwide. The
mechanism of favipiravir is the substitution with purine
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nucleotides in viral RNA after intracellular reactions
(Tarighi et al., 2021).
Darunavir is a nonpeptidyl HIV-1 protease inhibitor,
which is used for treatment of HIV infections by selectively
inhibiting Gag-Pol polyprotein cleavage (Tarighi et al.,
2021). Initial predictory studies on several commercially
available studies, including darunavir, reported as a
potential candidate (Beck et al., 2020), however the study
by De Meyer et al. showed no antiviral activity of darunavir
against SARS-CoV-2 (De Meyer et al., 2020). On the other
hand, several studies reported the use of darunavir along
with cobicistat (Valentina et al., 2020) and umifenovir
(Costanzo et al., 2020).
Neuraminidase inhibitor oseltamivir is used for
influenza A and B viruses, where it shows its activity by
blocking neuraminidase which plays a role in viral entry to
host cells as well as viral release from infected cells (Tarighi
et al., 2021). Although some initial studies reported that
oseltamivir has positive in treatment of COVID-19
patients, recent reports indicated its ineffectivity for
COVID-19 patients (Tan et al., 2020). Another antiviral
for influenza treatment, umifenovir, was also reported a
little benefit for the mild/moderate COVID-19 patients
when applied at 100 mg dose (Li et al., 2020b) but another
study at 200 mg three times daily, significantly shows
improvements in clinical and laboratory findings (Nojomi
et al., 2020), indicating the need for further studies with
larger sample sizes.
Remdesivir is a RNA polymerase inhibitor which is
shown as an effective therapeutic agent for treatment
of COVID-19 (Wang et al., 2020) and it is the first FDA
approved treatment for COVID-195. Its antiviral effects
are active by interfering viral replication inside the host
cell by forming a complex with SARS-CoV-2 NSP12
RNA dependent RNA polymerase (Rezagholizadeh et al.,
2021). According to a recent systematic review, remdesivir
could improve 28-day recovery rate as well as invasive
mechanical ventilation & extracorporeal membrane
oxygenation (Rezagholizadeh et al., 2021).
Other employed antiviral drugs include lopinavir,
atazanavir, emtricitabine and sofosbuvir (Frediansyah et
al., 2021). Among the antiviral drugs, remdesivir, lopinavir
and ritonavir have not shown better results than the
other treatment options used for moderately ill patients
according to the one of the largest randomized controlled
trials to date, WHO solidarity trials (Shoaib et al., 2021).
REGN-COV2; antibody cocktail drug involves
two monoclonal antibodies namely casirivimab and
imdevimab. These antibodies used in the drug REGNCOV2 for the treatment of COVID-19 target different parts
of the spike protein of the SARS-CoV-2 virus and bind
FDA (2020). FDA Approves First Treatment for COVID-19 [online].
Website https://www.fda.gov/news-events/press-announcements/
fda-approves-first-treatment-covid-19 [accessed April 27, 2021].
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tightly and noncompetitively to this protein. This prevents
the virus’s ability to infect healthy cells (Weinreich et al.,
2021). REGEN-COV2 drug has not been approved but has
been authorized for emergency use by FDA. Regeneron
reported that phase III trial of REGEN-COV2 antibody
cocktail decreased hospitalization and/or death by 70% in
nonhospitalized COVID-19 patients as well as shortened
the duration of symptoms by 4 days4.
5. Novel promising therapeutic methods for COVID-19
Novel promising therapeutics which are reviewed here,
are not yet authorized, or approved from FDA. Thus,
accepted treatment methods should be used as a priority
in COVID-19 patients with the recommendations of the
national or international guidelines.
5.1. Photodynamic therapy: alternative treatment modality against COVID-19
Photodynamic therapy (PDT) is a treatment modality that
uses the photosensitizer activated in the presence of visible
or near infrared light, and molecular oxygen to produce
reactive oxygen species (ROS) such as singlet oxygen (1O2)
and/or superoxide anion, hydroxyl radicals, and hydrogen
peroxide that eventually target cell death by apoptosis,
autophagy, or necrosis without or minimal injuring the
adjoining tissues (Ozlem-Caliskan and Bilgin, 2018; Kessel,
2019). PDT is approved for the treatment of certain cancers,
precancerous, and noncancerous disorders (Agostinis et
al., 2011). Additionally, this approach has been reported
to be effective for various types of microorganisms such
as bacteria (Gram-positive and Gram-negative), fungi,
parasites, and viruses (Jori et al., 2006).
Numerous classifications of photodynamic therapy,
for instance photodynamic inactivation, photodynamic
antimicrobial chemotherapy, antimicrobial PDT,
antibacterial PDT, antifungal PDT, antiviral PDT have
been used for treatment of bacterial, fungal, parasitic, and
viral disorders (Wiehe et al., 2019).
The main advantages of antimicrobial PDT are a
multi-target therapeutic approach and the absence of the
development of resistance mechanisms. These properties
are depending on the photodynamic action and affected
targets on the microorganisms (Almeida et al., 2020).
PDT has been applied successfully to inactivate viruses
and bacteriophages in the beginning of 20th century.
First clinical human trial used of PDT against viruses was
conducted in the early 1970s (Felber et al., 1973). However,
antiviral PDT has not been accepted easily because of
the limitations related to structure of photosensitizers,
target specificity, tissue penetration ability. Recently,
photoinactivation of viruses such as HIV, HSV, and
hepatitis virus families, in the blood and blood products is
the main use of antiviral PDT. Methylene blue, riboflavin,
curcumin, fullerenes perylene quinones, porphyrin, and
porphyrinoids are the photosensitizers for antiviral PDT

(Wiehe et al., 2019) but the efficiency of the treatment is
significantly dependent on the type of virus and where
the PDT applied. Therefore, the use of nanoparticle
technologies might improve the delivery, bioavailability,
selectivity, and functionality of current photosensitizers
while decreasing the side effects.
PDT is a two-stage procedure. After the administration
of a light sensitive photosensitizer, target cells/tissues are
irradiated with an appropriate wavelength of visible or near
infrared light, which activates a photosensitizer localized
in the target tissue in the presence of molecular oxygen
(Ozlem-Caliskan and Bilgin, 2018). The action mechanism
of PDT is diagrammatically explained in Figure 2. Briefly,
under the light irradiation, the photosensitizer in its
ground state absorbs photons of appropriate wavelength
and photosensitizer is excited to singlet state (PS1*).
Excited photosensitizer is very unstable and emits this
excess energy as fluorescence and/or heat. Alternatively,
an excited photosensitizer may form a more stable excited
triplet state (PS3*) via an intersystem crossing. Subsequently,
excess energy of the photosensitizer in triplet state can
be lost by the emission of phosphorescence, generation
of heat or attending of the biochemical reactions. In the
presence of biological substrate and molecular oxygen the
photosensitizer in triplet state can decay to ground state
via type I and type II reactions leading to the formation
of singlet oxygen and reactive oxygen species (O2.-, HO.,
H2O2) (Grossweiner et al., 2005). During the sensitization
of photosensitizers, Type I and Type II processes occur
simultaneously and compete with each other. The singlet
oxygen plays a more important role in PDT for cancers,
but reactive oxygen species (ROS) is more effective for
the inactivation of microorganism via PDT. Highly
reactive oxygen species lead to cellular toxicity in the
process of apoptosis, necrosis, autophagy and immune
cell death. PDT mediated cell death pathways depend on
the location of photosensitizers in the target cells such as
mitochondria, cell membrane, lysosomes or endoplasmic
reticulum. Singlet oxygen and ROS can also cause
destruction of cancer vasculature and produces an acute
inflammatory response that attracts leukocytes such as
dendritic cells and neutrophils. At the end, these oxygen
species cause cellular photo-damage which can activate a
repair mechanism or lead to cell death when the damage is
beyond repair (Grossweiner et al., 2005). In antiviral PDT,
ROS are mainly generated and reacted with nucleic acids
(DNA or RNA), virus proteins and viral lipids (Wiehe et
al., 2019). Then, virus inactivation is formed that inhibiting
virus binding with the host and ultimately ending the virus
life cycle.
The most used medical application of antiviral
PDT is decontamination of blood products by mostly
using riboflavin, methylene blue (MB) and amotoselen
(Schlenke, 2014). Aminolevulinic acid, hematoporphyrin
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Figure 2. Action mechanism of photodynamic therapy (modified from Jablonski diagram). PS, ground state of the photosensitizer;
PS1*, excited singlet state of photosensitizer; PS3*, excited triplet state of photosensitizer; ROS, reactive oxygen species; O2, ground
state of oxygen; 1O2, singlet oxygen; O2−., superoxide; HO., hydroxyl radicals; H2O2, hydrogen peroxide.

derivatives and MB mediated PDT are predominantly
used for the treatment of both local Herpes simplex virus
infections and Human papillomavirus infections (viral
warts, condylomata accuminata). MB, a positively charge
molecule, can cross the viral envelop and intercalate with
viral nucleic acid which are negatively charged. Porphyrins
have high affinity to viral proteins and lipids. Thus, MB and
Radachlorin mediated PDT inhibits SARS-CoV-2 in vitro
(Svyatchenko et al., 2021). MB has ability to inhibit the
SARS-CoV-2 spike protein and its receptor ACE2 which
is crucial in inactivating the virus. MB mediated PDT
has been used in dental disorders for decades, but PDT
was clinically used for oral manifestation of COVID-19
recently. MB mediated PDT with photobiomodulation
therapy, known as low level laser therapy, were shown
effectiveness in the management of COVID-19 related
orofacial lesions. The combination of both methods causes
for removing the viruses, enhancing tissue oxygenation
and reducing or inhibiting cytokine storm. Therefore,
improvements in tissue repair and pain reduction have
been observed in these patients (Teixeira et al., 2021).
PDT can be used for the treatment of COVID-19
infections in the respiratory tract. An extracorporeallyilluminated PDT was used against bacterial pneumonia
by using extracorporeal illumination at 780 nm light
with nebulized indocyanine green (Kassab et al., 2019).
PDT protocols in respiratory tract are still investigated
for clinical patients (Dias et al., 2020). Thus, PDT
against COVID-19 may reduce the microbial load in the
respiratory tract in near future. Also, if a photosensitizer
like indocyanine green can deliver to the lungs, it may be
irradiated by a laser. At the end, PDT generates singlet
oxygen and ROS to initiate the virus inactivation.
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The photosensitizer, light, and molecular oxygen
play an important role for PDT against viruses such as
COVID-19. Depending on the advancing technologies,
various photosensitizers in nanoparticles and their
physicochemical reactions of the target cells can be used
for increasing the therapeutic efficacy of viral PDT. The
amount oxygen consumption is directly related to light
dose and source of light. Therefore, oxygen monitoring
within the target cells or tissue may also crucial for PDT.
Although there are significant challenges for PDT, it has a
potential use for the management of COVID-19.
5.2. Nanotechnology based methods
Nanotechnology can play an important role in COVID-19
treatment, as previous antiviral studies utilizing
nanotechnology showed (Tang et al., 2021). The most
important advantage of nanomaterials antiviral research
is the similarity of size where the size of SARS-CoV-2
(60−140 nm) (Zhu et al., 2020) is similar to FDA approved
nanomaterials (Tang et al., 2021). Other advantages include
the use of nanomaterials in delivery of drugs, enhancing
the stability of vaccines (Tang et al., 2021). Besides its
advantages in diagnosis (Vahedifard and Chakravarthy,
2021), applications in treatment are currently being
researched. When it comes to antiviral treatment, it
should be noted that all the antiviral formulations used for
other viral infections are being challenged for treatment
of COVID-19, by the limited intracellular intake/
uptake of the molecules (Ansari et al., 2020), therefore
nanoformulations can be very effective for targeting the
viruses and targeted delivery of the antiviral molecule
(Lembo et al., 2018). Potential use of nanotechnology in
the treatment is the inhibition of virus-cell interaction,
membrane fusion, cell internalization, transcription and
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translation, and activating intracellular mechanisms
(Cardoso et al., 2020; Mainardes and Diedrich, 2020).
5.2.1. Inorganic nanoparticles
Inorganic nanoparticles forms a large family of materials,
including metal oxide nanoparticles (Kalaycıoğlu et al.,
2020, Kaygusuz and Erim, 2020), silica nanoparticles
(Farjadian et al., 2019) and metallic nanoparticles (Zhang et
al., 2016). Some nanomaterials such as silver nanoparticles
have direct effect as virucidal activity (Zhou et al., 2021).
The efficiency of silver nanoparticles as antiviral agents is
well studied for viruses such as HIV and HSV and even
practical applications are proposed (Mohammed Fayaz et
al., 2012). Gold nanoparticles are also promising thanks
to the good surface chemistry properties for health
applications and other properties (Rashidzadeh et al.,
2021). The antiviral mechanism of gold nanoparticles is
including the blocking of gp120 attachment with CD4 for
viral entry inhibition and the antiviral mechanism of silver
nanoparticles is corresponding to viral entry inhibition,
attachment or replication (Maduray and Parboosing,
2020). Other metallic nanoparticles with antiviral activity
include zinc, iron and copper. Other advantages of
metallic nanoparticles are ease of manufacture, surface
modification and size tuning.
As for metal oxides, they are mostly used for detection
purposes, but the treatment reports are also present.
When nanomaterials show enzyme-like characteristics,
they are called nanozymes (Wu et al., 2019). For example
iron oxide nanoparticles show enzyme-like activity by
peroxidase and catalase activities and already reported
inactivation of influenza (Gao et al., 2017; Qin et al., 2019).
Other example to metal oxide nanoparticles with antiviral
activities is TiO2 (Akhtar et al., 2019).
Inorganic nanoparticles have several limitations for
effective delivery and avoiding toxicity. These parameters
include surface properties, size, charge, and shape of the
nanoparticles (Vahedifard and Chakravarthy, 2021). By
the means of targeted delivery, one option is the intranasal
delivery of the nanoparticles and other options are targeted
drug delivery and specific small interfering RNA (siRNA)
delivery (Itani et al., 2020). Based on the approach and the
aim, the design of the surface properties of the inorganic
nanoparticle should be precisely carried out.
5.2.2. Lipid based nanotechnology
Liposomes are spherical vesicles consisting of at least one
lipid bilayer where the size can be in rage of 15 to 1000
nm (Chakravarty and Vora, 2020) and can be described as
most common targeted drug delivery agents (Sercombe et
al., 2015). Drug delivery formulations based on liposomes
include intracellular functional protein delivery (Chatin et
al., 2015), delivery of anti-cancer drugs (Olusanya et al.,
2018), gene delivery (Balazs and Godbey, 2011), vaccine
delivery (Schwendener, 2014), delivery of antibiotics

(Gonzalez Gomez and Hosseinidoust, 2020) as well as
antiviral delivery (Düzgüneş et al., 2005).
Since various water soluble molecules such as
proteins, peptides, carbohydrates or nucleic acids can be
entrapped within the aqueous inner shell of liposomes,
and lipophilic compounds are entrapped within the lipid
bilayer, the liposomes are very advantageous in vaccine
delivery systems (Schwendener, 2014). After the outbreak
of COVID-19 pandemic, several vaccine formulations
have been developed and some of them (BNT162b2,
mRNA1273) already contains lipid nanoparticles
(Milane and Amiji, 2021) to deliver mRNA. mRNA1273
by Moderna contains proprietary ionic lipid SM-1026
and BNT162b2 by Pfizer/BioNTech contains the lipid
mixture ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)
bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3phosphocholine, and cholesterol7. On the other hand, the
stability of lipid based nanoparticles can be a drawback.
In order to improve the chemical and physical stability of
lipid bilayer systems, a recent study utilizes immobilization
in a crystalline zeolitic-imidazole framework exoskeleton
(Herbert et al., 2021).
Another study by McKay et al. reports the development
of self-amplifying RNA encoding the SARS-CoV-2 spike
protein encapsulated lipid nanoparticles as a vaccine
where the results are very promising with high cellular
responses (McKay et al., 2020).
To the best of our knowledge, currently, there are no
specific and verified antiviral drugs for SARS-CoV-2,
however there are hypotheses for the design of Tatpeptide conjugated repurposed drug by lipid based nanodelivery (Ansari et al., 2020). Another study by Wang et
al. proposes the use of low-water solubility anthelminthic
drug niclosamide delivery by lipid nanoparticles for
inhibition of SARS-CoV-2 replication (Wang et al., 2021).
6. Conclusion
From the influenza pandemic (H1N1) in 1918 to the
new coronavirus (SARS-CoV-2) pandemic that emerged
in 2019, a suitable technique for the early detection of
pathogenic viruses has not yet been developed. The
current diagnostic methods have various limitations
including the cost of the equipment and reagents, need
of technical expert, low specificity to determine SARSModerna (2020). mRNA-1273-P301-Protocol [online]. Website
https://www.modernatx.com/sites/default/files/mRNA-1273-P301Protocol.pdf [accessed May 8, 2021].
6

Medicines and Healthcare Products Regulatory Agency (MHRA)
(2021). Information for Healthcare Professionals on Pfizer/
BioNTech COVID-19 vaccine [online]. Website https://www.gov.uk/
government/publications/regulatory-approval-of-pfizer-biontechvaccine-for-covid-19/information-for-healthcare-professionals-onpfizerbiontech-covid-19-vaccine [accessed May 8, 2021].
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CoV-2 and still they may cause false negative or false
positives results. Moreover, although there is not yet
a proven and globally known treatment method for
COVID-19 disease caused by the SARS-CoV-2 virus,
there are medications recommended by official protocols
for treatment in different countries. This review focuses on
the current diagnosis and treatment strategies used against
SARS-CoV-2, and new diagnosis and treatment methods

developed as alternatives to current ones. Thus, it will shed
light on early diagnosis and effective treatment strategies
against possible outbreaks that may occur in the future due
to similar coronaviruses.
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